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ABSTRACT
Clinical and laboratory parameters including blood and cerebrospinal fluid (CSF) neopterin 
were investigated in human-T-lymphotropic-virus-type-I associated-myelopathy/tropical-
spastic-paraparesis-HAM/TSP and in HTLV-I carriers. HAM/TSP (n = 11, 2 males/9 females, 
median age = 48 years), recently diagnosed HTLV-I carriers (n = 21, 15 females/6 males, 
median age = 44 years), healthy individuals (n = 20, 10 males/10 females, median age = 34.6 
years) from the Brazilian Amazon (Manaus, Amazonas State) were investigated. Neopterin 
was measured (IBL ELISA Neopterin, Germany) in serum samples of all the participants, in 
CSF of 9 HAM/TSP patients as well as in 6 carriers. In HAM/TSP patients, CSF cell counts, 
protein and glucose were measured, the Osame’s motor-disability-score/OMDS was determined, 
and brain/spinal cord magnetic-resonance-imaging (MRI) was performed. HAM/TSP patients 
had normal CSF glucose, leukocyte counts; and normal protein levels predominated. Brain-
MRI showed white-matter lesions in 7 out of 11 HAM/TSP patients. OMDS varied from 2-8: 
9 were able to walk, 2 were wheel-chair-users. The median serum neopterin concentration 
in HAM/TSP patients was 6.6 nmol/ L; min. 2.8- max. 12.5 nmol/ L); was lower in carriers 
(4.3 nmol/L; min. 2.7- max. 7.2 nmol/ L) as well as in healthy participants (4.7 nmol/ L; min. 
2.7- max. 8.0 nmol/ L) (p < 0.05). CSF neopterin concentrations in HAM/TSP patients were 
higher than in serum samples, and higher compared to carriers (p < 0.05). Carriers had similar 
serum-CSF neopterin concentrations compared to healthy participants. Variable clinical and 
laboratory profiles were seen in HAM/TSP patients, however our results support the neopterin 
measurement as a potential biomarker of disease activity.
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INTRODUCTION
Worldwide, around 5-10 million people may be infected with the human T cell 
lymphotropic virus type I (HTLV-I) with high prevalences in southern Japan, parts 
of West Africa, the Caribbean Islands, Melanesia and South America1,2. Brazil is 
considered one of the largest endemic areas of HTLV-I and associated diseases, and 
the city of Salvador, capital of the State of Bahia presents the highest prevalence 
(1.76% in the overall population)3. Nevertheless, HTLV-I worldwide prevalence is 
probably underestimated since it remains uninvestigated in many large and highly 
populated regions4. In endemic areas, mother to child transmission, which is mainly 
linked to extended breastfeeding is a main route of HTLV-I transmission, but sexual 
intercourse, blood transfusion and contaminated needle sharing are other forms of 
transmission4. Most HTLV-I infected individuals remain lifelong asymptomatic 
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carriers, while 2-5% may develop adult T-cell leukemia/
ATL and 0.25-3.8% may develop HTLV-I-associated 
myelopathy/tropical spastic paraparesis (HAM/TSP)4. 
HAM/TSP, the most common neurological manifestation 
of HTLV-1 is a slowly progressive inflammatory 
demyelinating disease of the central nervous system 
(CNS) with gradual spastic paraparesis, neurogenic bladder 
disturbances, and other sensory signs5. High proviral loads 
are associated with faster disease progression, increased 
proliferation and migration of HTLV-I infected lymphocytes 
to the CNS6. HAM/TSP is an immune-mediated disease 
of the CNS, but its precise immunopathogenic mechanism 
is not completely understood. CD4+ T cells represent 
the main virus reservoirs and infiltrates of virus infected 
CD4+/CD8+ T cells in the spinal cord and increased 
production of inflammatory cytokines such as IFNγ, TNFα 
and IL1β have been described6,7,8. Alterations in magnetic 
resonance imaging (MRI) of the brain and spinal cord 
in HAM/TSP are probably a result of the virus-induced 
inflammatory process9,10. Several laboratory alterations in 
systemic and cerebrospinal fluid (CSF) have been described 
in HAM/TSP patients11,12,13. 
In neuro-inflammatory diseases, neopterin concentration 
in biological specimens has been proposed as a marker 
of disease activity indicating cellular-mediated immunity 
(CMI) activation. Neopterin, a pteridine derived from 
guanosine triphosphate is produced by activated monocytes-
macrophages and dendritic cells following IFNγ production 
by TH1 cells14,15. Neopterin has been associated with 
HAM/TSP diagnosis and prognosis indicating the degree 
of intrathecal CMI activation16,17.
This study describes clinical and laboratory parameters 
which include serum and CSF neopterin measurements 
in HAM/TSP patients and in asymptomatic anti HTLV-I 
positive carriers from the Brazilian Amazon. 
MATERIAL AND METHODS
HAM/TSP Patients and HTLV-I Carriers
Fifty-two participants from the city of Manaus 
(Amazonas State, North Brazil) were investigated: 11 HAM/
TSP patients, 21 HTLV-I carriers and 20 healthy individuals. 
HAM/TSP patients (> 18 years old, positive anti HTLV-I in 
serum and CSF, confirmed by western blot or PCR) were 
recruited at the Neurology Ambulatory, Getúlio Vargas 
University Hospital, Federal University of Amazonas. The 
following exclusion criteria were considered: neoplastic 
or vascular diseases of the spinal cord, neurodegenerative 
or demyelinating diseases, myelopathy associated with 
vitamin B12 deficiency, infectious myelopathies, auto-
immune diseases, positive serology to CMV, HBV, HCV, 
HIV, HTLV-II, syphilis or Chagas disease; history of 
malaria or pulmonary tuberculosis; previous treatment 
with corticosteroids or other immune modulating drug. 
The clinical diagnosis of HAM/TSP was conducted by 
an expert neurologist (Takatani M) according to criteria 
proposed by the World Health Organization18. Patients 
were classified according to the Osame’s motor disability 
score/OMDS grading incapacity level  from 0 (normal 
gait and running), to 10 (completely bedridden)19. 
MRI of the brain and spinal column was performed 
for the differential diagnosis with other brain or spinal 
cord pathologies as multiple sclerosis. Gender, age, 
duration of disease and symptoms were also recorded. 
Recently diagnosed, asymptomatic anti HTLV-I 
positive carriers, confirmed by western-blot or PCR were 
recruited among blood donors of a main public blood 
bank (Hematology and Hemotherapy Foundation from 
Amazonas State /FHEMOAM), Manaus, Amazonas 
State. HTLV-I carriers (both genders, > 18 years old, 
without myelopathy-related symptoms) were included. 
Exclusion criteria were: chronic liver, kidney or heart 
disease, pneumopathy, dermatological diseases, any sign 
of infectious disease such as fever, auto-immune diseases, 
positive serology for HBV, HCV, HIV, HTLV-II, syphilis, 
Chagas disease and pregnancy. 
For comparisons of serum neopterin levels, 20 healthy 
individuals (10 males, 10 females; median age = 34.6 years, 
min.23- max. 44) were recruited among blood donors at 
FHEMOAM. They were all seronegative for HIV, HCV, 
HBV, Chagas disease, syphilis and HTLV-I/II. 
Clinical Specimens
HAM/TSP patients had venous blood and CSF collected 
at Getúlio Vargas University Hospital; HTLV-I carriers had 
biological samples collected at FHEMOAM. CSF (8mL) 
was collected by lumbar puncture performed by a single 
expert professional (Takatani M); only samples devoid 
of red blood cells were used. For HAM/TSP patients 
and HTLV-I carriers who consented, paired blood and 
CSF samples were collected within a two-hours period. 
Biological samples were aliquoted and stored at -80oC 
until tested. For ethical reasons, only blood samples were 
collected from healthy participants. 
HTLV-I Diagnosis and Neopterin Measurements 
HTLV-I status of all the participants was determined 
by ELISA (MUREX HTLV I+ II GE80/81, MUREX 
Diagnosticos, Brasil) and confirmed by western blot (HTLV 
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BLOT 2.4, Genelabs Diagnostics, Singapore) or PCR as 
previously described20. 
Competitive ELISA was used to evaluate neopterin 
levels in serum and CSF (IBL neopterin ELISA, Hamburg, 
Germany), the normal serum neopterin concentration being 
< 10 nmol/ L. As previously reported, the normal neopterin 
CSF value was considered 4.2 nmol/ L.21 CSF was also used 
for routine laboratory tests (cell count, total protein, glucose 
levels). Comorbidities and other exclusion conditions were 
also evaluated through the following laboratory parameters: 
blood cell count, erythrocyte sedimentation rate/ESR, 
lipidogram, glucose, urea, creatinine, AST, ALT, ALP, 
prothrombin and bilirubin levels. 
Statistical Analysis
Exploratory data analyses including mean, medians, 
box-plots, interquartile ranges, frequencies were calculated 
by using the t student test, Pearson’s correlation. Kruskal 
Wallis and Man Whitney tests were used for both 
HAM/TSP and asymptomatic carriers data; when applicable 
the Graph Pad Prism 6 was used; p values < 0.05 were 
considered significant. 
RESULTS
Clinical and Demographic Profiles of HAM/TSP 
Patients and HTLV-I Carriers 
Among HAM/TSP patients (Table 1), females 
predominated; the median age was 48 years (27-66 years), 
the duration of symptoms ranged from 1-16 years and the 
Osame’s motor disability score/OMDS varied from 2 to 8. 
Most HAM/TSP patients (9/11, 81,9%) were able to walk 
(OMDS ≤ 6) while 2 (18,1%) were wheel chair-users. The 
lowest disability scores were seen in patients with the shortest 
duration of disease (patients # 7 and 10: 1 and 3 years of 
disease, respectively). All the HAM/TSP patients reported 
difficulty to walk, around half (54.5%) had low-back pain 
and paresthesia in the lower limbs was the most common 
sensory complaint (45.4%). The two male HAM/TSP 
patients did not report erectile or bladder dysfunction while 
8 out of 9 female patients reported bladder dysfunction, 
with urinary frequency alterations, urgency or incontinence. 
Among 21 HTLV-I carriers (15 females, 6 males), the 
median age was 44 years (20-54 years). 
Leukocyte, Protein and Glucose levels in CSF of HAM/
TSP patients and HTLV-I Carriers
Three HAM/TSP patients had CSF protein levels above 
the normal range (patients # 6, 7 and 8, Table 1) and patients 
# 3, 4 and 9 presented CSF protein concentration slightly 
higher than the normal range. The highest CSF protein 
concentration was seen in the most recently diagnosed patient 
(# 7: 1 year of disease). All the HAM/TSP patients had normal 
levels CSF glucose, four patients had CSF leukocyte counts 
above the normal range (# 4, 8, 9, 10), and lymphocytes 
represented the predominating cell population. In HTLV-I 
carriers (Table 2), only case # 2 had normal CSF protein level, 
all the carriers had normal CSF glucose levels and leukocyte 
cell counts were above the normal limit in 2 out of 6 carriers. 
Table 1 - Main demographic, clinical and laboratory features of HAM/TSP patients.















1 F 56 4 10 6.5 7.8 32 50 4
2 F 52 4 5 6.2 16.5 40 11 3
3 F 66 8 16 35 166 44 47 4
4 F 62 4 6 2.8 7.8 41 41 21
5 F 55 5 8 6.8 NA NA NA NA
6 F 44 5 15 4.8 12 45.7 50 1
7 M 48 2 1 12 20 73 58 3
8 M 27 7 4 10 17 47 58 18
9 F 40 4 7 4 17 42 53 13
10 F 40 2 3 12.5 18 18 50 7
11 F 44 6 14 12.5 26 16 26 1
M: male, F: Female; OMDS: Osame’s motor disability score; CSF: cerebrospinal fluid; Reference values for: serum neopterin 
concentration<=10nmol/L, CSF neopterin concentration<= 4.2nmol/L, CSF protein concentration=15-40mg/dl; CSF glucose 
levels=2/3 of serum glucose levels or 50-70mg/dl, CSF cell count<=4 cell/mm3; NA= data not available because patient did not 
consent CSF collection.
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Neurologic Characterization of HAM/TSP Patients
Brain MRI of 7 out of 11 HAM/TSP patients (# 1, 2, 3, 
4, 5, 9, 10; Table 1) presented unspecific lesions in the white 
matter (WM) described as gliosis. Patient #1 showed multiple 
white matter confluent lesions extended from periventricular 
to subcortical locations, suggestive of a demyelinating disease 
(Figure 1) without lesions in the posterior fossa or in the 
thoracic spine. This 56 years old female patient, with 10 years 
of disease, had a motor incapacity score = 4 (needs support 
while using stairs but could walk without assistance). Only one 
patient (# 3) showed spinal cord MRI alteration while no sign 
of spinal cord swelling was seen in the other patients. Cerebral 
atrophy was observed in one HAM/TSP patient (# 5, Table 1) 
without association with dementia. No correlation between 
the symptoms and the number of WM lesions was found, and 
no evidence of cerebellar dysfunction was detected. Cranial 
nerve functions were normal in all the patients. 
Neopterin Levels in Peripheral Blood and CSF in HAM/
TSP Patients and HTLV-I Carriers 
Serum neopterin levels in healthy individuals (n = 20, 
median = 4.7 nmol/ L; min. 2.7- max. 8.0 nmol/L) and 
asymptomatic HTLV-I carriers were similar (n = 21; 
median = 4.3 nmol /L; min. 2.7- max. 7.2 nmol/ L) (Figure 2A; 
p > 0.05). However serum neopterin concentrations in 
HAM/TSP patients (n = 11; median = 6.8; min. 2.8-max. 
35 nmol/ L, Table 1, Fig. 2A) were higher compared to the 
HTLV-I carriers (p = 0.0033) and the healthy participants 
(p < 0.0001). 
In HAM/TSP patients, the median serum concentration 
of neopterin was 6.8 nmol/ L (2.8-35 nmol/ L) while the 
median CSF neopterin was 17 nmol/ L (7.8-166 nmol/ L), 
Table 1, Figures 2A, 2B). In HTLV-I carriers (n = 6) normal 
serum and CSF neopterin levels were detected (serum: 
median = 4.4 nmol/ L; min. 2.7- max. 7.2 nmol/ L; CSF 
median = 3.1 nmol/L; min. 2.2 – max. 5.2 nmol/ L). 
CSF neopterin concentrations in HAM/TSP patients 
(n = 10) were higher when compared to HTLV-I carriers 
(p = 0.0016, Fig. 2A). In HAM/TSP, paired serum-CSF 
analysis of neopterin showed consistently higher levels in 
CFS (p = 0.024, Figures 2A, 2B). In contrast, in HTLV-I 
carriers (n = 6), the median neopterin concentration in 
serum and in CSF was similar (p > 0.05) (Figures 2A, 
2C). However, in HTVL-I carriers a heterogeneous pattern 
was seen: in 4 out of 6 carriers neopterin levels in serum 
samples were higher compared to CSF, whereas in two other 
carriers, neopterin levels were higher in CSF compared to 
the serum samples.
In HAM/TSP patients, a moderate correlation was 
found between CSF neopterin and motor incapacity level/
OMDS (r = 0.62, p = 0.043). In HAM/TSP patients we 
have also analyzed if the difference of neopterin levels 
between the two compartments (CSF minus serum) would 
correlate with the data available. These analyses showed a 
moderate correlation between the difference of neopterin 
in CSF minus serum and OMDS (r = 0.62, p = 0.05). 
No correlation was found between CSF neopterin and 
duration of disease, CSF cell count, CSF glucose, CSF 
protein concentration (p > 0.05). No correlation was found 
Table 2 - Main demographic and laboratory features of HTLV-I carriers* 










Cell count CSF 
cel/mm3
1 M 38 4.3 2.2 56 68 2
2 F 46 3.6 2.7 39 77 0
3 F 47 4.5 3.2 75 61 8
4 F 35 4.8 5.2 98 57 14
5 M 54 6.6 3.0 88 78 1
6 F 36 2.8 4.5 52 67 3
* HTLV-I carriers who consented to have CSF collected; M: male, F: Female;  Age (years); CSF: cerebrospinal fluid; Reference 
values for: serum neopterin concentration ≤ 10 nmol/L, CSF neopterin concentration ≤ 4.2 nmol/L, CSF protein concentration = 
15-40 mg/dL; CSF glucose levels = 2/3 of serum glucose levels or 50-70 mg/dL, CSF cell count ≤ 4 cell/mm3.
Figure 1 - Brain magnetic resonance imaging (MRI, axial flair) 
showing hyper intense multiple lesions in the periventricular 
and subcortical white matter in a 56-year-old female HAM/
TSP patient with 10 years of disease symptoms and motor 
disability grade 4.
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between serum neopterin levels and duration of disease or 
motor incapacity level (p > 0.05). In asymptomatic HTLV-I 
carriers no correlation was observed between CSF neopterin 
concentrations and CSF cell counts, protein or glucose 
concentrations.
DISCUSSION
Brazil represents one of the largest endemic areas 
for HTLV-I, however there are scarce data from many 
areas in the country including the Amazonas State. In 
this context, our study provides detailed laboratory and 
clinical features of HAM/TSP patients from the Brazilian 
Amazon. As previously reported, in our study young adult 
females predominated in both symptomatic HAM/TSP 
patients and asymptomatic HTLV-I carriers22. Females 
are reported to have higher incidences of HAM/TSP with 
faster disease progression especially when symptoms 
precede menopause, suggesting a role for sex hormones23. 
A Brazilian nationwide survey (1994-1995) has shown 
that the ratio of infected females increased from South to 
North24. It is also stated that, regardless of different socio-
economic and cultural environments, in highly endemic 
regions, HTLV-I seroprevalence increases gradually with 
age, especially in women. This increment may be associated 
with the overtime accumulation of risky sexual exposure 
or of other transmission risk factors25,26,27. A study showed 
that among HTLV-I positive blood donor carriers from Iran, 
males predominated, probably reflecting the lower tradition 
of female blood donors in this country, whereas among 
HAM/TSP patients, females predominated28. 
We acknowledge limitations in our study including 
the small sample size and the lack of HTLV-I proviral 
loads; however, our data on serum and CSF neopterin 
measurements confirms its role as a marker of central 
nervous system disease with inflammatory activity29. In 
our study, HAM/TSP patients had higher serum neopterin 
concentrations compared to HTLV-I carriers and healthy 
participants. Moreover, in HAM/TSP patients, paired 
serum-CSF neopterin analysis showed higher values in 
CSF, which were also higher compared to CSF neopterin 
in asymptomatic carriers. In contrast, among HTLV-I 
carriers, serum and CSF neopterin concentrations were 
similar. HAM/TSP patients compared to HTLV-I carriers 
had higher neopterin concentrations both in serum and in 
CSF, indicating that a less invasive sample as the peripheral 
Figure 2 - (A).  Neopterin concentrations in serum of healthy individuals, in serum and cerebrospinal fluid (CSF)  of HTLV-I 
asymptomatic carriers and of HAM/TSP patients. Boxes encompass 25th and 75th percentiles of the distribution; black lines within 
boxes refer to the median values; (B). Neopterin concentrations in paired serum and CSF samples of HAM/TSP patients; (C). 
Neopterin concentrations in paired serum and CSF samples of HTLV-I carriers.
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blood may also give valuable information about the level 
of CNS/spinal cord inflammation and CMI activation. Our 
results corroborate previous data indicating that neopterin 
represents another potential marker of disease activity in 
HAM/TSP patients with potential applications to assess 
the disease progression and to monitor the treatment 
efficacy17,30. 
In fact, in our study group, the oldest HAM/TSP patient (66 
years old) had the longest duration of symptoms (16 years), 
and the highest motor disability score (OMDS = 8). This 
patient had the highest neopterin concentrations in both 
serum (35 nmol/L) and CSF (166 nmol/ L). This patient had 
a slowly progressive myelopathy, which evolved rapidly to 
superior member incapacity in the last 6 months prior to the 
study enrollment. Serial brain and spinal cord MRI did not 
reveal any alteration that could be possibly related to this 
rapid clinical deterioration. During the disease course, no 
immunosuppressive or corticosteroid therapy was prescribed. 
There is no cure for HAM/TSP but different treatments can 
alleviate symptoms, so that biomarkers to indicate the risk and 
the rate of disease progression may have a potential clinical 
relevance and application31. 
Among routine laboratory tests, moderate pleocytosis 
and raised protein content represent the most frequent CSF 
findings in HAM/TSP, especially during recent clinical 
manifestations, and these parameters tend to gradually 
decline32. Mild CSF mononuclear pleocytosis and discrete 
increase of CSF protein have been reported11. In our HAM/
TSP patients, mild pleocytosis, mainly of mononuclear cells 
was reported, as previously described18. A study in 20 HAM/
TSP Brazilian patients described mild pleocytosis in 30%13. 
In our HAM/TSP patients the highest CSF protein level was 
detected in the patient with the most recent diagnosis (# 7, 
1 year, Table 1) indicating the possible association of CSF 
inflammatory markers with recent disease33. Interestingly, 
in our study, in 5 out of 6 asymptomatic carriers who had 
CSF collected, protein levels were abnormal, probably 
reflecting a more recent infection. In our HAM/TSP patients 
and asymptomatic carriers, there was lack of correlation 
between CSF neopterin concentrations and CSF cell 
counts, protein or glucose concentrations, similarly to 
data previously described34. However, one study showed 
correlation between both CSF neopterin and pleocytosis/ 
glucose levels in 41 HAM/TSP patients35. In our small 
group of HAM/TSP, time since diagnosis ranged widely and 
it is possible that differences in viral loads, which were not 
available, may have influenced these correlations. 
A slowly progressive disease course is considered the 
hallmark of HAM/TSP33,36. However, the rate at which 
symptoms progress varies widely including patients that 
deteriorate rapidly while others remain clinically stable over 
the years. Therefore, biomarkers able to predict the level 
and speed of disease progression are important to identify 
patients at higher risk and can provide clinicians with a 
more precise prognosis and more appropriate treatment. A 
retrospective study has compared the prognostic value of 
several potential biomarkers for HAM/TSP in peripheral 
blood and CSF of deteriorating and stable HAM/TSP 
patients37. This study has identified CSF levels of CXCL10, 
CXCL9 and neopterin as promising candidate prognostic 
biomarkers for HAM/TSP progression, with better 
correlations than HTLV-I proviral loads in peripheral blood 
mononuclear cells. These results corroborate the importance 
of neopterin as a biomarker for HAM/TSP as shown in 
our study. Moreover, these results suggest that assessing 
multiple prognostic biomarkers in both, blood and CSF, 
may better discriminate patients with higher risk of disease 
progression and in need of a more effective treatment. 
Most HAM/TSP patients from our study had slowly 
progressive symptoms, except for one patient (#8, Table 
1, 27 years old male, OMDS=7, 4 years of symptoms) that 
progressed rapidly. Disease progression in HAM/TSP can 
reflect an active inflammatory process in the spinal cord. In 
fact, this patient had elevated neopterin levels in serum and 
CSF indicating inflammation and reactivation or maintenance 
of the inflammatory process which has been reported in 
HAM/TSP patients with long disease duration35. Mononuclear 
inflammatory infiltrates were reported in the white and 
gray matter of the spinal cord in a 74 years old, female 
HAM/TSP patient with 29 years of disease36. However, two 
autopsy cases of HAM/TSP patients reporting 15 and 21 
years of symptoms showed very few inflammatory cells in the 
spinal cord and brain38. Another autopsy study of a HAM/TSP 
patient with 28 years of disease showed degenerative lesions 
in the spinal cord without inflammation39. Corticosteroid 
and immunosuppressive treatment for HAM/TSP patients 
reduce the intensity of the inflammatory reaction and 
consequently the tissue damage, however prolonging 
the reparative process40. In our observational study, no 
HAM/TSP patient was under immunosuppressive or 
corticosteroid treatment as these interventions are known 
to influence the inflammatory marker levels. Disease 
progression in HAM/TSP is considered multifactorial and 
the potential host and viral factors that influence the natural 
course of disease are not completely understood41 and are 
beyond the scope of our study.
Brain and spinal cord MRI is highly sensitive to detect 
and control CNS abnormalities and complications and is 
important for the diagnosis and treatment follow up in 
HAM/TSP42,31. Unspecific periventricular and subcortical 
white matter (WM) lesions on brain MRI are frequent 
in HAM/TSP patients41. It has been suggested that WM 
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lesions may represent small vessel vasculitis and since 
they predominate in middle aged/older patients, they could 
be due to degenerative microangiopathy43,44. Among our 
HAM/TSP patients, most showed small lesions in the 
subcortical and periventricular WM, however these lesions 
were not associated with symptoms, as reported45,46. MRI 
findings of 28 Brazilian HAM/TSP patients, mostly with 
severe neurological incapacity, showed hyper intense 
lesions in brain WM, indirect atrophy signs and occasionally 
spinal cord lesions44. Among our HAM/TSP patients, no 
sign of spinal cord swelling was reported, whereas only one 
patient showed spinal cord atrophy, however variable levels 
of spinal cord abnormalities have been reported46,47. For 
logistic and operational reasons, our study did not include 
MRI to investigate possible WM abnormalities in the spinal 
cord and brain of HTLV-I carriers and in negative controls. 
In conclusion, our study shows a wide range of 
clinical and laboratory profiles among HAM/TSP patients, 
suggesting the influence of host and viral factors. Consistent 
with the literature, no association was found between 
cerebral WM lesions and disease duration or degree of motor 
disability. Our laboratory data reinforce the importance of 
neopterin measurement as a biomarker associated with CNS 
disease activity and as a potential biomarker of CNS disease 
progression. Biomarkers of CNS activity can be helpful in 
the clinical management of high-risk HAM/TSP patients 
helping to anticipate interventions to minimize spinal cord 
damage and to monitor treatment efficacy. 
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